Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Single Arm Phase II Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)

NCT02779101 is registered in ClinicalTrials.gov with Prof. Dr. Matthias Preusser as lead sponsor.

NCT NCT02779101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02779101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Single Arm Phase II Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Lead sponsor
Prof. Dr. Matthias Preusser
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2016
Completion date
June 30, 2019
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma